What Researchers Did
Researchers conducted a randomized controlled trial to evaluate the effect of hyperbaric oxygen therapy (HBOT) on symptoms, brain microstructure, and functionality in veterans with treatment-resistant post-traumatic stress disorder (PTSD).
What They Found
Of 35 randomized veterans, 29 completed the protocol, with the hyperbaric oxygen therapy (HBOT) group showing significant improvement in clinician-administered PTSD scale-V (CAPS-V) scores (P<0.0001) compared to controls. The HBOT group also demonstrated significant improvements in brief symptom inventory (BSI) scores (P=0.024) and BECK depression inventory (BDI) scores (P=0.01), along with improved brain activity in fMRI.
What This Means for Canadian Patients
For Canadian patients, particularly veterans struggling with treatment-resistant PTSD, hyperbaric oxygen therapy (HBOT) could represent a promising new therapeutic option. This therapy may offer a practical, non-pharmacological approach to alleviate symptoms and potentially improve brain function, warranting further investigation in a Canadian context.
Canadian Relevance
This study has no direct Canadian connection as it was not conducted in Canada nor involved Canadian participants or researchers.
Study Limitations
A limitation of this study is its relatively small sample size and the lack of an active control group, which could impact the generalizability of the findings.